Two Sigma Investments LP Decreases Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Two Sigma Investments LP cut its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 25.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 501,400 shares of the life sciences company's stock after selling 170,047 shares during the period. Two Sigma Investments LP owned 0.65% of Integra LifeSciences worth $11,372,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new stake in Integra LifeSciences in the fourth quarter valued at approximately $8,967,000. Principal Financial Group Inc. boosted its holdings in Integra LifeSciences by 5.5% in the fourth quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock valued at $9,603,000 after acquiring an additional 22,000 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Integra LifeSciences by 7.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after acquiring an additional 913 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after acquiring an additional 2,800 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Integra LifeSciences by 9.9% in the fourth quarter. Northern Trust Corp now owns 892,425 shares of the life sciences company's stock valued at $20,240,000 after acquiring an additional 80,090 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Down 1.9%

Shares of IART traded down $0.24 during trading hours on Thursday, reaching $12.46. The stock had a trading volume of 103,201 shares, compared to its average volume of 1,039,479. Integra LifeSciences Holdings Co. has a 12 month low of $11.60 and a 12 month high of $32.66. The firm has a 50-day simple moving average of $16.43 and a 200 day simple moving average of $21.11. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $968.29 million, a price-to-earnings ratio of -138.10, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. During the same quarter in the prior year, the business earned $0.55 earnings per share. Integra LifeSciences's revenue for the quarter was up 3.7% on a year-over-year basis. Equities research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on IART. JPMorgan Chase & Co. reduced their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Truist Financial reduced their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Wells Fargo & Company reduced their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. JMP Securities reduced their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Finally, Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has an average rating of "Hold" and an average target price of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.